Literature DB >> 29382535

MEHP promotes the proliferation of cervical cancer via GPER mediated activation of Akt.

Weili Yang1, Wen Tan1, Jingfei Zheng1, Biyan Zhang1, Hongfeng Li1, Xuehe Li2.   

Abstract

Cervical cancer is the fourth leading cause of cancer death in females worldwide and the second leading cause of mortality among women. Estrogenic signals can regulate the progression of cervical cancer, however, little is known about the mono-2-ethyhexyl phthalate (MEHP), an environmental xenoestrogen, on the development of cervical cancers. Our present data showed that nanomolar concentrations of MEHP can trigger the proliferation, while not invasion, of cervical cancer HeLa and SiHa cells, which was confirmed by the results that MEHP can also increase the expression of proliferating cell nuclear antigen (PCNA). MEHP treatment can increase the phosphorylation and nuclear localization of Akt, while had no effect on the activation of ERK1/2 or p65. Targeted inhibition of Akt via its specific siRNA or inhibitor can reverse MEHP induced cell proliferation. In addition, the inhibitor of G protein coupled estrogen receptor (GPER), while not estrogen receptor α (ERα), can abolish MEHP induced phosphorylation of Akt and cell proliferation, suggesting that GPER is involved in MEHP induced activation of Akt. Collectively, our data showed that MEHP can trigger the progression of cervical cancer via activation of GPER/Akt. It suggested that MEHP exposure is also an important risk factor for development and progression of cervical cancers.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Akt; Cervical cancer; GPER; MEHP; Proliferation

Mesh:

Substances:

Year:  2018        PMID: 29382535     DOI: 10.1016/j.ejphar.2018.01.040

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Cytoplasmic G Protein-Coupled Estrogen Receptor 1 as a Prognostic Indicator of Breast Cancer: A Meta-Analysis.

Authors:  Duo Zhang; Jinpeng Wang; Hong Chen; Shunchao Yan
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  [Mass spectrometry-based identification of new serum biomarkers in patients with multidrug resistant pulmonary tuberculosis].

Authors:  Dongzi Lin; Wei Wang; Feng Qiu; Yumei Li; Xiaolin Yu; Bingyao Lin; Yinwen Chen; Chunyan Lei; Yan Ma; Jincheng Zeng; Jie Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

3.  SMAGP a novel biomarker of cervical cancer development and progression.

Authors:  Yongqin Jia; Haiyu Li; Geli Liu; Fangzhou Song
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.147

Review 4.  G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer.

Authors:  Shen Xu; Shan Yu; Daming Dong; Leo Tsz On Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-25       Impact factor: 5.555

Review 5.  Perturbation of Nuclear Hormone Receptors by Endocrine Disrupting Chemicals: Mechanisms and Pathological Consequences of Exposure.

Authors:  Julie M Hall; Callie W Greco
Journal:  Cells       Date:  2019-12-19       Impact factor: 6.600

6.  Ultrasound Microbubble-Mediated microRNA-505 Regulates Cervical Cancer Cell Growth via AKT2.

Authors:  Leilei Xu; Qin Zhang; Changhua Li; Fu Hua; Xiaoping Liu
Journal:  Anal Cell Pathol (Amst)       Date:  2020-10-15       Impact factor: 2.916

Review 7.  Expression and Role of the G Protein-Coupled Estrogen Receptor (GPR30/GPER) in the Development and Immune Response in Female Reproductive Cancers.

Authors:  Christian David Hernández-Silva; Julio César Villegas-Pineda; Ana Laura Pereira-Suárez
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-20       Impact factor: 5.555

Review 8.  Effects and Mechanisms of Phthalates' Action on Reproductive Processes and Reproductive Health: A Literature Review.

Authors:  Henrieta Hlisníková; Ida Petrovičová; Branislav Kolena; Miroslava Šidlovská; Alexander Sirotkin
Journal:  Int J Environ Res Public Health       Date:  2020-09-18       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.